The online version of this article (doi:10.1007/s40120-014-0022-9) contains supplementary material, which is available to authorized users.
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current clinical diagnostic tools are often ineffective in accurately diagnosing AD. However, new advances in diagnostic imaging, particularly positron emission tomography (PET) amyloid imaging, have shown increased sensitivity and specificity, as well as high inter-reader agreement. The most commonly studied tracer, PiB-C11, has shown high affinity binding to amyloid, but is limited in its use outside of research due to its short half-life. Instead, development of other PET ligands with increased half-life, such as fluorine-18-labeled (18F) tracers, allows for more widespread use of PET in clinical settings. In particular, recent phase II and III trials of 18F-florbetaben have demonstrated the high accuracy of this PET tracer in identifying amyloid accumulation. This paper will examine the techniques of amyloid imaging, focusing particularly on the recently approved 18F-florbetaben.
Miniño AM. Death in the United States, 2011. NCHS Data Brief, 115. http://www.cdc.gov/nchs/data/databriefs/db115.htm. Accessed Nov 11, 2014.
Banarjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. Int J Geriatr Psychiatry. 2009;24:748–54. CrossRef
Nair AK, Sabbagh MN. Amyloid imaging. In: Nair AK, Sabbagh MN, editors. Geriatric neurology. Chichester: Wiley-Blackwell; 2014. CrossRef
Cure S, Abrams K, Belger M, Dell’agnello G, Happich M. Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer’s Disease and other dementia using autopsy as standard of truth. J Alzheimers Dis. 2014;42:169–82. PubMed
Fleisher AS, Drzezga A. Functional Imaging in Dementia. In: Nair AK, Sabbagh MN, editors. Geriatric neurology. Chichester: Wiley-Blackwell; 2014.
Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40. PubMed
Johnson KA, Minoshima S, Bohnen NI, Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:e-1–16. CrossRef
Barthel H, Sabri O. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26:117–21. PubMed
Ong KT, Villemagne VL, Bahar-Fuchs A, et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2014. doi: 10.1136/jnnp-2014-308094
- Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain
Marwan N. Sabbagh
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II